Reyes León-Cachón RB, Ascacio-Martínez JÁ, Barrera-Saldaña HA

Idioma: Ingles.
Referencias bibliográficas: 63
Paginas: 364-376
Archivo PDF: 297.71 Kb.

RESUMEN

La variación genómica explica las diferencias de los individuos para responder a los tratamientos farmacológicos. El campo de la predicción de las respuestas a fármacos dispone de diversas estrategias y métodos, entre ellos: microsomas hepáticos, modelos celulares, monitoreo de fármacos sonda, ensayos con proteínas recombinantes y recientemente el uso de dispositivos diagnósticos de la era genómica, como microarreglos o DNAchips. Un área de la medicina genómica se enfoca en la identificación de polimorfismos genéticos y mutaciones en genes que intervienen en el desarrollo y progresión de las enfermedades. Otra parte se concentra en el desarrollo de pruebas genéticas de acompañamiento a las prescripciones médicas para predecir cómo ciertos pacientes responden a las terapias con un agente farmacológico dado.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526.

2. Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 2001; 482: 11-19.

3. Motulsky AG. Drug reactions enzymes and biochemical genetics. J Am Med Assoc 1957; 165: 835-7.

4. Motulsky AG, Qi M. Pharmacogenetics, pharmacogenomics and ecogenetics. J Zhejiang Univ Sci B 2006; 7: 169-70.

5. Marshall A. Genset-Abbott deal heralds pharmacogenomics era. Nat Biotechnol 1997; 15: 829-30.

6. Joseph T, Dipiro RLT, Gary C Yee, Gary R Matzke, Barbara G, Wells L, Posey M. Pharmacogenetics. In: Pharmacotherapy A pathophysiologic approach. Posey LM (ed.); New York: The McGraw-Hill; 2008, p. 2559.

7. O’Shaughnessy KM. HapMap, pharmacogenomics, and the goal of personalized prescribing. Br J Clin Pharmacol 2006; 61: 783-6.

8. Lander ES, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.

9. Venter JC, et al. The sequence of the human genome. Science 2001; 291: 1304-51.

10. Science, U.S.D.o.E.O.o. Genomics and Its Impact on Science and Society:The Human Genome Project and Beyond. Human Genome Program A Primer, 12 (2008).

11. Collins FS, et al. New goals for the U.S. Human Genome Project: 1998-2003. Science 1998; 282: 682-9.

12. Pang AW, et al. Towards a comprehensive structural variation map of an individual human genome. Genome Biol 2010; 11: R52.

13. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-73.

14. Lewin B. Genes IX. Sudbury, Massachusetts: Jones And Bartlett Publishers; 2008.

15. Madsen BE, Villesen P, Wiuf C. Short tandem repeats and genetic variation. Methods Mol Biol 2010; 628: 297-306.

16. Hall IP. Pharmacogenetics, pharmacogenomics and airway disease. Respir Res2002; 3: 10.

17. Redon R, et al. Global variation in copy number in the human genome. Nature 2006; 444: 444-54.

18. Li J, et al. Whole genome distribution and ethnic differentiation of copy number variation in Caucasian and Asian populations. PLoS One 2009; 4: e7958.

19. Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002; 113: 746-50.

20. Paine MF, et al. The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 2006; 34: 880-6.

21. Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol Appl Pharmacol 2005; 207: 52-6.

22. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006; 25: 1679-91.

23. Reyes-Hernandez OD, et al. A comparative study of CYP3A4 polymorphisms in Mexican Amerindian and Mestizo populations. Pharmacology 2008; 81: 97-103.

24. Qin J, Jones RC, Ramakrishnan R. Studying copy number variations using a nanofluidic platform. Nucleic Acids Res 2008; 36: e116.

25. Casner PR. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans. J Clin Pharmacol 2005; 45: 1230-5.

26. Gamazon ER, Huang RS, Dolan ME, Cox NJ. Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol 2011; 12: R46.

27. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57: 119-37.

28. Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci 2005; 360: 1563-70.

29. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr Top Med Chem 2004; 4: 1385-98.

30. Sakurai A, et al. Quantitative structure-activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1). Biochemistry 2007; 46: 7678-93.

31. Putnam WS, Woo JM, Huang Y, Benet LZ. Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. J Clin Pharmacol 2005; 45: 411-21.

32. Brenner SS, Klotz U. P-glycoprotein function in the elderly. Eur J Clin Pharmacol 2004; 60: 97-102.

33. Sekine T, Cha SH, Endou H. The multispecific organic anion transporter (OAT) family. Pflugers Arch 2000; 440: 337-50.

34. Niemi M, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005; 77: 468-78.

35. Thompson MD, Siminovitch KA, Cole DE. G proteincoupled receptor pharmacogenetics. Methods Mol Biol 2008; 448: 139-85.

36. Limdi NA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African- American and European-American patients on warfarin. Clin Pharmacol Ther 2008; 83: 312-21.

37. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-05.

38. Pirmohamed M, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19.

39. Nelson MR, et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J 2009; 9: 23-33.

40. Donato MT, O’connor JE. Monography. 2009.

41. Administration, U.S.F.a.D. Pharmacogenomics and its role in drug safety. FDA Drug Safety Newsletter 2008; 1: 24-6.

42. Invitrogen. P450-3A4 BACULOSOMES® Reagents, rHuman.

43. Castell JV, Gómez-Lechón MJ. Drug Metabolism and Carcinogen Activation Studies with Human Genetically Engineered Cells. In: José VC, María José GL (eds.). In vitro Methods in Pharmaceutical Research. San Diego: Academic Press; 1996, p. 432-49.

44. Landsiedel R, Fabian E, Tralau T, Luch A. Chemical toxicity testing in vitro using cytochrome P450-expressing cell lines, such as human CYP1B1. Nat Protocols 2011; 6: 677-88.

45. Hong H, Goodsaid F, Shi L, Tong W. Molecular biomarkers: a US FDA effort. Biomark Med 2010; 4: 215-25.

46. Ekins S, Vanden-Branden M, Ring BJ, Wrighton SA. Examination of purported probes of human CYP2B6. Pharmacogenetics 1997; 7: 165-79.

47. Pelkonen O, et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008; 82: 667-715.

48. Masimirembwa CM, Thompson R, Andersson TB. In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. Comb Chem High Throughput Screen 2001; 4: 245-63.

49. Lee SJ, et al. Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug Metab Dispos 2009; 37: 2262-9.

50. Preissner S, et al. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res 2010; 38: D237- D243.

51. McGinnity DF, Riley RJ. Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochem Soc Trans 2001; 29: 135-9.

52. Turpeinen M, et al. A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy- 2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos 2009; 37: 1017-24.

53. Stringer RA, Strain-Damerell C, Nicklin P, Houston JB. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab Dispos 2009; 37: 1025-34.

54. Kudzma EC, Carey ET. Pharmacogenomics: Personalizing Drug Therapy. American Journal of Nursing 2009; 109: 50-7.

55. Dumond JB, et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 2010; 87: 735-42.

56. Dumaual C, et al. Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. Pharmacogenomics 2007; 8: 293-305.

57. Tejedor D, et al. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 2005; 51: 1137-44.

58. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009; 59: 42-55.

59. Mega JL, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.

60. Barrera-Saldaña HA. Nanofarmalab: Un DNAChip para la predicción de la respuesta a tratamientos farmacológicos (FONCICYT Fondo: C0002, Convocatoria: C0002-2008-01, Solicitud: 000000000095773, Vitagénesis S.A. (Monterrey, NL), Progenika Biopharma S.A. (Derio, España), Innopsys S.A.(Carbone, Francia) y Laboratorios Silanes S.A. (México, DF). Octubre 2009-Junio 2013).

61. Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med 2011; 78: 243-57.

62. U.S. Department of Health and Human Services, F.a.D.A., Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies. Clinical Pharmacology 2011.

63. Mallal S, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-79.